Current Report Filing (8-k)
12 November 2021 - 11:06PM
Edgar (US Regulatory)
0001744659
false
0001744659
2021-11-12
2021-11-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12, 2021
Akero Therapeutics, Inc.
(Exact name of registrant as specified in its
charter)
Delaware
|
|
001-38944
|
|
81-5266573
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
601 Gateway Boulevard, Suite 350
South San Francisco, CA
|
94080
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code (650) 487-6488
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading
symbol(s)
|
Name of each exchange on which registered
|
Common Stock, par value $0.0001 per share
|
AKRO
|
The Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 2.02
|
Results of Operations and Financial Condition
|
On November 12, 2021, Akero Therapeutics, Inc. announced its financial
results for the quarter ended September 30, 2021. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report
on Form 8-K.
The information in this Current Report on Form 8-K and Exhibit 99.1
attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 12, 2021
|
AKERO THERAPEUTICS, INC.
|
|
|
|
|
By:
|
/s/ Andrew Cheng
|
|
Name:
|
Andrew Cheng, M.D., Ph.D.
|
|
Title:
|
President and Chief Executive Officer
|
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akero Therapeutics (NASDAQ:AKRO)
Historical Stock Chart
From Apr 2023 to Apr 2024